Fibrocell Science to Present at Barclays Global Healthcare Conference 2014

EXTON, Pa.--(BUSINESS WIRE)--Fibrocell Science (NYSEMKT:FCSC), an autologous cell therapy company primarily focused on developing first-in-class treatments for skin diseases and conditions with high unmet medical needs, today announced that David Pernock, chairman and chief executive officer of Fibrocell Science, will present at the Barclays Global Healthcare Conference 2014 at 2:30 pm EDT on Wednesday, March 12, 2014, at the Loews Hotel in Miami. Mr. Pernock will discuss the company’s autologous fibroblast technology, its therapeutic candidates in development, and its collaboration with Intrexon Corporation (NYSE:XON) to develop genetically-modified personalized biologics.

A live webcast of the presentation will be available on Fibrocell's website at www.fibrocellscience.com. The presentation will be archived on the company's website and available for 90 days.

About Fibrocell Science, Inc.

Fibrocell Science, Inc. (NYSEMKT:FCSC) is an autologous cell therapy company primarily focused on developing first-in-class treatments for skin diseases and conditions with high unmet medical needs. Based on its proprietary autologous fibroblast technology, Fibrocell is pursuing breakthrough medical applications of azficel-T for restrictive burn scarring and vocal cord scarring. The company’s collaboration with Intrexon Corporation (NYSE:XON), a leader in synthetic biology, includes using genetically-modified fibroblasts for treating orphan skin diseases for which there are no currently approved products. For additional information, visit www.fibrocellscience.com.